BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia

@article{Geffen2009BL1020AN,
  title={BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia},
  author={Yona Geffen and Abraham Nudelman and Irit Gil-ad and Ada Rephaeli and Abraham Weizman},
  journal={European Neuropsychopharmacology},
  year={2009},
  volume={19},
  pages={1-13}
}
UNLABELLED Reduced brain gamma-amino-butyric acid (GABA) participates in the pathogenesis of schizophrenia. GABA scarcely penetrates the brain. We evaluated the pharmacological properties of BL-1020, a novel GABA ester of perphenazine. Oral BL-1020 or perphenazine were assessed in acute and subchronic schizophrenia rat models. Catalepsy, serum prolactin, receptor binding profile and cortical (PFC), hippocampal (Hip) and dopamine (DA) levels were determined. Radioactive [14C] labeled BL-1020 was… Expand
BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans
TLDR
Pharmacokinetic-pharmacodynamic analysis predicted that oral once daily administration of 32 mg BL-1020 would result in D(2) ROs ranging from 52 to 66% at a steady state, which did not raise any safety concern. Expand
An Open-Label Tolerability Study of BL-1020 Antipsychotic: A Novel Gamma Aminobutyric Acid Ester of Perphenazine
TLDR
It is suggested that 20 to 40 mg/d of BL-1020 is associated with clinically relevant improvement of psychosis with no worsening of EPS and support further testing in randomized controlled trials. Expand
Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission
TLDR
The data suggest that adjunctive treatment with a NET inhibitor may enhance the therapeutic effect of low-dose olanzapine in schizophrenia without increasing EPS liability and add an antidepressant action, thus in principle allowing for a dose reduction of olanZapine with a concomitant reduction of dose-related side effects, such as EPS and weight gain. Expand
PERPHENAZINE 4-AMINOBUTYRATE MESYLATE Dopamine D 2 Receptor Antagonist GABAA Receptor Agonist Treatment of Schizophrenia
  • 2012
Schizophrenia is a lifelong disorder characterized by bizarre delusions, lack of motivation, reduction in spontaneous speech, social withdrawal and some affective symptoms. PerphenazineExpand
BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D 2 receptor occupancy
BL-1020 is a potentially novel antipsychotic, which comprises the typical antipsychotic perphenazine linked by an ester bound to γ-aminobutyric acid (GABA), intending a simultaneous dopamine-2 (D2)Expand
Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats
TLDR
SYA013 was shown to inhibit both d-amphetamine-induced locomotor activity in rats and conditioned avoidance response in rats in a dose dependent manner and in the case of CAR, without producing any escape failure responses (EFRs), two tests predictive of antipsychotic action, indicating that SYA013 has a pharmacological profile with the potential for use in the treatment of neuropsychiatric diseases. Expand
A role of GABA analogues in the treatment of neurological diseases.
TLDR
Over recent years, there has been increasing interest in the synthesis and pharmacological effect of new GABA derivatives, which can be considered as potent drugs in the treatment of neurodegenerative disorders. Expand
Investigational dopamine antagonists for the treatment of schizophrenia
TLDR
The expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes. Expand
Emerging drugs for schizophrenia
TLDR
Although clinicians will have to have considerable patience before truly novel anti-schizophrenia treatments become obtainable, a number of interesting leads with considerable theoretical potential are being explored. Expand
Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder
  • R. McIntyre
  • Medicine
  • Expert review of neurotherapeutics
  • 2010
TLDR
Its efficacy in mania is unequivocally established as is the sustaining of its acute antimanic effect, and its antidepressant and recurrence prevention effects in bipolar disorder are under investigation, as is its possible role in major depressive disorder. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 49 REFERENCES
Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release
TLDR
These results suggest that, in combination with VPA, both typical and atypical APDs produce greater increases in prefrontal cortical DA release than either type of drug alone via a mechanism dependent upon 5-HT(1A) receptor activation. Expand
A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
  • B. Yee, R. Keist, +10 authors U. Rudolph
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2005
TLDR
The results suggest that agonists acting at alpha3-containing GABA(A) receptors may constitute an avenue for an effective treatment of sensorimotor-gating deficits in various psychiatric conditions, including schizophrenia. Expand
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity
TLDR
The present results demonstrate that the 5-HT(2C) agonist, CP-809,101, has a pharmacological profile similar to that of the atypical antipsychotics with low extrapyramidal symptom liability. Expand
Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression.
BACKGROUND: Post-mortem studies with brain samples of schizophrenic patients led revealed altered GABA-ergic markers like reduced expression of the GABA transporter GAT-1. Whether this effect is dueExpand
5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release
TLDR
The results suggest that the atypical APDs via 5‐HT2A and D2 receptor blockade, regardless of intrinsic 5-HT1A affinity, may promote the ability of 5- HT1A receptor stimulation to increase mPFC DA release, and provide additional evidence that coadministration of 5‐ HT2A antagonists and typical APDs, which are D2 antagonists, may facilitate 5‐ht1A agonist activity. Expand
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
TLDR
The perphenazine and fluphenazine GABA esters 3 and 4 evaluated in rat models for antipsychotic activity displayed a significant decrease of catalepsy associated with increased prolactin blood levels, forming a prototype of novel antipsychotics possessing GABAergic activity. Expand
Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
TLDR
From the combined data, GABA agonist drugs tend to be associated with some degree of improvement in TD symptoms, but also with side effects such as confusion and sedation and a deterioration of the person's mental state. Expand
Antiepileptic drugs in schizophrenia: a review
TLDR
New antiepileptics (e.g., gabapentin, oxcarbazepine, topiramate, vigabatrin) present a promise as potential adjuncts to neuroleptic treatment in resistant symptoms of schizophrenia. Expand
GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses
  • E. Keverne
  • Psychology, Medicine
  • Brain Research Bulletin
  • 1999
TLDR
This article attempts to draw together an underlying causation across the various forms of psychotic disorder and, by integrating this with what is known about the genetics, neuroanatomy and neuropharmacology of the positive symptoms in schizophrenia, produce a broader understanding. Expand
The GABAergic system in schizophrenia.
  • B. Blum, J. Mann
  • Biology, Medicine
  • The international journal of neuropsychopharmacology
  • 2002
TLDR
Substantial evidence argues for a defect in the GABAergic system of the frontal cortex in schizophrenia which is limited to the parvalbumin-class of GABAergic interneurons. Expand
...
1
2
3
4
5
...